BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cheah E, Huang JG. Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World J Gastroenterol 2023; 29(10): 1539-1550 [PMID: 36970587 DOI: 10.3748/wjg.v29.i10.1539]
URL: https://www.wjgnet.com/1007-9327/full/v29/i10/1539.htm
Number Citing Articles
1
Luyao Liu, Fan Zhao, Dandan Han, Xin Lü, Gang Wu, Yanglei Yi. Liquiritigenin ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function, reducing endoplasmic reticulum stress and modulating gut microbiotaJournal of Functional Foods 2024; 122: 106541 doi: 10.1016/j.jff.2024.106541
2
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovationsWorld Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
3
Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments at the year-end of 2023World Journal of Gastroenterology 2024; 30(1): 1-8 doi: 10.3748/wjg.v30.i1.1
4
Danny Con, Peter De Cruz. Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling studyIntestinal Research 2024; 22(4): 439 doi: 10.5217/ir.2023.00175
5
Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang, Qing-Chun Zhao. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysisWorld Journal of Gastrointestinal Surgery 2024; 16(2): 571-584 doi: 10.4240/wjgs.v16.i2.571
6
Daniel Schweckendiek, Gerhard Rogler. Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?Digestion 2024; 105(6): 411 doi: 10.1159/000540421